Published in Drug Week, July 2nd, 2004
This agreement was reached under the FDA's special protocol assessment (SPA) process.
"We have been working closely with the FDA to reach agreement on a study that, if successful, would support the approval of Ranexa in the United States, and we are pleased to have reached agreement under the SPA process for a single...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.